Open AccessPredicting Corticosteroid-Free Biologic Remission with Vedolizumab in Crohn’s Disease
Author(s) -
Akbar K. Waljee,
Boang Liu,
Kay Sauder,
Ji Zhu,
Shail M. Govani,
Ryan W. Stidham,
Peter Higgins
Publication year - 2018
Publication title -
inflammatory bowel diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.932
H-Index - 146
eISSN - 1536-4844
pISSN - 1078-0998
DOI - 10.1093/ibd/izy031
Subject(s) - vedolizumab , medicine , corticosteroid , cohort , receiver operating characteristic , crohn's disease , clinical endpoint , inflammatory bowel disease , clinical trial , ulcerative colitis , gastroenterology , disease
Vedolizumab (VDZ) is effective for Crohn's disease (CD) but costly and is slow to produce remission. Early knowledge of whether vedolizumab is likely to succeed is valuable for physicians, patients, and insurers.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom